Slynd is NOT FDA-Approved for Endometriosis
Slynd (drospirenone 4 mg) is FDA-indicated solely for contraception in females of reproductive potential, not for the treatment of endometriosis 1. However, emerging evidence suggests it may be effective for managing endometriosis-associated symptoms as an off-label use.
FDA-Approved Indication
The FDA label clearly states that Slynd's only indication is "for use by females of reproductive potential to prevent pregnancy" 1. There is no mention of endometriosis treatment in the approved indications.
Off-Label Use: Supporting Evidence
While not FDA-approved for endometriosis, clinical data supports its potential efficacy:
Adolescent Population Data
- In a retrospective study of 61 adolescents with endometriosis (97% laparoscopically confirmed), 67% reported less pain at follow-up when treated with continuous drospirenone 2
- 52% achieved absence of bleeding/spotting 2
- The medication was well-tolerated, with only 25% discontinuing (most commonly due to breakthrough bleeding) 2
- Another study of 136 adolescents showed 84.6% of dysmenorrhea patients and 77.8% of pelvic pain patients reported resolution or improvement 3
Combination Formulations (Different from Slynd)
The evidence base is stronger for combined oral contraceptives containing drospirenone with ethinyl estradiol, which are FDA-approved for acne but used off-label for endometriosis 4:
- ACOG guidelines (2000) recommend oral contraceptives as effective for endometriosis pain relief (Level B evidence) 4
- Multiple studies demonstrate efficacy of drospirenone/ethinyl estradiol combinations for endometriosis-associated pain 5, 6, 7
Clinical Considerations
When to Consider Slynd for Endometriosis (Off-Label)
- Patients with contraindications to estrogen (this is where Slynd has particular advantage) 2
- Adolescents and young adults with laparoscopically-confirmed endometriosis
- Patients who have failed other progestin-only options (norethindrone, norethindrone acetate)
Key Monitoring Requirements
Before initiating:
- Check serum potassium in patients on medications that increase potassium or those with risk factors for hyperkalemia 1
- Assess for contraindications: renal impairment, adrenal insufficiency, hepatic impairment 1
During treatment:
- Monitor for breakthrough bleeding (occurs in 64.4% at cycle 1, decreasing to 40.3% by cycle 13) 1
- Reassess potassium during first treatment cycle if at risk 1
- Evaluate persistent bleeding for pregnancy or malignancy 1
Common Pitfalls
- Do not use in patients with renal impairment - this is an absolute contraindication due to hyperkalemia risk 1
- Expect significant breakthrough bleeding initially; counsel patients that this typically improves over 3-6 months 1, 3
- Unlike combined oral contraceptives, Slynd requires 7 days of backup contraception if started >1 day after menses 8
Bottom Line
Use Slynd for endometriosis only as off-label therapy, particularly when estrogen-containing contraceptives are contraindicated. The strongest evidence supports combined drospirenone/ethinyl estradiol formulations for endometriosis pain 4, but emerging data suggests progestin-only drospirenone (Slynd) may be effective, especially in adolescents 2, 3. Screen carefully for hyperkalemia risk factors before prescribing, and counsel patients about expected breakthrough bleeding that typically improves over time.